Showing results (51-60 of 4,234) with videos related to
Sort By:
Pageof 424
Journal for Immunotherapy of Cancer|May 17, 2020
Nivolumab and dinutuximab beta in two patients with refractory neuroblastomaKaroline Ehlert, Ina Hansjuergens, Andreas Zinke, et al.Journal for Immunotherapy of Cancer|June 13, 2020
Identification of PD1-mediated regulation of antitumor antigen response in patients with NSCLC using the trans vivo DTH assayDiego A Lema, Ewa Jankowska-Gan, Nan Sethakorn, et al.Journal for Immunotherapy of Cancer|June 14, 2020
Rechallenge patients with immune checkpoint inhibitors following severe immune-related adverse events: review of the literature and suggested prophylactic strategyJohn Haanen, Marc Ernstoff, Yinghong Wang, et al.Journal for Immunotherapy of Cancer|June 14, 2020
IL-15 superagonist RLI has potent immunostimulatory properties on NK cells: implications for antimetastatic treatmentMélanie Desbois, Coralie Béal, Mélinda Charrier, et al.Journal for Immunotherapy of Cancer|May 29, 2020
Granzyme B PET imaging of immune-mediated tumor killing as a tool for understanding immunotherapy responseThomas LaSalle, Emily E Austin, Grant Rigney, et al.Journal for Immunotherapy of Cancer|June 1, 2020
Interplay between glucocorticoids and tumor-infiltrating lymphocytes on the prognosis of adrenocortical carcinomaLaura-Sophie Landwehr, Barbara Altieri, Jochen Schreiner, et al.Journal for Immunotherapy of Cancer|June 1, 2020
Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodiesJoseph Kauer, Sebastian Hörner, Lukas Osburg, et al.Journal for Immunotherapy of Cancer|May 22, 2020
COVID-19 and lung cancer: risks, mechanisms and treatment interactionsAlfredo Addeo, Michel Obeid, Alex FriedlaenderJournal for Immunotherapy of Cancer|May 23, 2020
Personalized neoantigen-based immunotherapy for advanced collecting duct carcinoma: case reportYongyi Zeng, Wei Zhang, Zhenli Li, et al.Journal for Immunotherapy of Cancer|May 26, 2020
Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trialJieqiong Liu, Qiang Liu, Ying Li, et al.Pageof 424